Analyzing Synergy Pharmaceuticals (SGYP) & The Competition

Synergy Pharmaceuticals (NASDAQ: SGYP) is one of 295 public companies in the “Bio Therapeutic Drugs” industry, but how does it weigh in compared to its peers? We will compare Synergy Pharmaceuticals to similar companies based on the strength of its valuation, earnings, profitability, risk, analyst recommendations, institutional ownership and dividends.

Profitability

This table compares Synergy Pharmaceuticals and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Synergy Pharmaceuticals -3,193.13% -402.67% -220.23%
Synergy Pharmaceuticals Competitors -11,931.74% -481.62% -43.80%

Volatility & Risk

Synergy Pharmaceuticals has a beta of 1064.55, suggesting that its share price is 106,355% more volatile than the S&P 500. Comparatively, Synergy Pharmaceuticals’ peers have a beta of 6.66, suggesting that their average share price is 566% more volatile than the S&P 500.

Earnings and Valuation

This table compares Synergy Pharmaceuticals and its peers gross revenue, earnings per share and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
Synergy Pharmaceuticals $2.41 million -$216.83 million -2.42
Synergy Pharmaceuticals Competitors $260.16 million $66.28 million -6.83

Synergy Pharmaceuticals’ peers have higher revenue and earnings than Synergy Pharmaceuticals. Synergy Pharmaceuticals is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Analyst Ratings

This is a summary of recent ratings and price targets for Synergy Pharmaceuticals and its peers, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Synergy Pharmaceuticals 1 0 9 0 2.80
Synergy Pharmaceuticals Competitors 758 3016 11142 227 2.72

Synergy Pharmaceuticals presently has a consensus target price of $8.90, indicating a potential upside of 216.73%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 33.72%. Given Synergy Pharmaceuticals’ stronger consensus rating and higher probable upside, research analysts plainly believe Synergy Pharmaceuticals is more favorable than its peers.

Insider & Institutional Ownership

71.5% of Synergy Pharmaceuticals shares are held by institutional investors. Comparatively, 51.0% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 3.8% of Synergy Pharmaceuticals shares are held by insiders. Comparatively, 16.9% of shares of all “Bio Therapeutic Drugs” companies are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Synergy Pharmaceuticals beats its peers on 7 of the 12 factors compared.

About Synergy Pharmaceuticals

Synergy Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of gastrointestinal (GI) therapies. The Company’s product candidates include TRULANCE (plecanatide) and dolcanatide. The Company is engaged in the discovery, research and development efforts around analogs of uroguanylin for the treatment of GI diseases and disorders. TRULANCE is designed to replicate the function of uroguanylin. Dolcanatide is being evaluated for inflammatory bowel disease (IBD). TRULANCE is approved in the United States under the trademark name TRULANCE, for the treatment of adults with chronic idiopathic constipation (CIC). In addition, it is developing TRULANCE for the treatment of adults with irritable bowel syndrome with constipation (IBS-C). Dolcanatide is designed to be an analog of uroguanylin with enhanced resistance to standard digestive breakdown by proteases in the intestine.

Receive News & Ratings for Synergy Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synergy Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply